Cargando…
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
SIMPLE SUMMARY: Since its recognition in 2016 as a distinct entity among acute myeloid leukemia (AML), no consensus on treatment has been established for managing blastic dendritic cell neoplasm (BPDCN). Patients seem sensitive to standard chemotherapies, but relapses and resistance development ofte...
Autores principales: | Poussard, Margaux, Angelot-Delettre, Fanny, Deconinck, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367503/ https://www.ncbi.nlm.nih.gov/pubmed/35954431 http://dx.doi.org/10.3390/cancers14153767 |
Ejemplares similares
-
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020) -
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
por: Philippe, Laure, et al.
Publicado: (2017) -
Do Corticosteroids Still Have a Place in the Treatment of Chronic Pain?
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2018) -
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
por: Caël, Blandine, et al.
Publicado: (2022) -
Early detection of transformation to BPDCN in a patient with MDS
por: Chamoun, Kamal, et al.
Publicado: (2018)